Analysts Set CryoPort, Inc. (NASDAQ:CYRX) PT at $18.00

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $18.00.

Several brokerages have commented on CYRX. Weiss Ratings lowered shares of CryoPort from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 17th. Roth Capital reissued a “buy” rating and issued a $21.00 target price on shares of CryoPort in a report on Friday, August 7th. KeyCorp increased their price target on shares of CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Guggenheim lifted their price objective on CryoPort from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th.

CryoPort Trading Down 4.6%

Shares of NASDAQ:CYRX opened at $16.34 on Thursday. The company has a 50-day moving average price of $15.54 and a 200-day moving average price of $12.35. The company has a market cap of $827.62 million, a price-to-earnings ratio of -18.16 and a beta of 1.89. CryoPort has a 12 month low of $7.61 and a 12 month high of $17.20.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%.The business had revenue of $48.97 million during the quarter, compared to the consensus estimate of $48.18 million. As a group, research analysts forecast that CryoPort will post -0.83 EPS for the current fiscal year.

Insider Buying and Selling at CryoPort

In related news, Director Ramkumar Mandalam sold 23,214 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $15.44, for a total transaction of $358,424.16. Following the completion of the sale, the director directly owned 67,894 shares in the company, valued at approximately $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Robert Stefanovich sold 169,427 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the transaction, the chief financial officer owned 109,850 shares in the company, valued at $1,787,259.50. The trade was a 60.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 256,441 shares of company stock valued at $4,051,923. 9.50% of the stock is owned by corporate insiders.

Institutional Trading of CryoPort

Several hedge funds have recently bought and sold shares of CYRX. California State Teachers Retirement System raised its stake in CryoPort by 305.0% during the 2nd quarter. California State Teachers Retirement System now owns 10,707 shares of the company’s stock worth $168,000 after acquiring an additional 8,063 shares during the period. Highland Investment Advisors LLC bought a new position in shares of CryoPort during the 2nd quarter valued at approximately $306,000. Kerrisdale Advisers LLC purchased a new position in shares of CryoPort in the 2nd quarter worth $355,000. Headlands Technologies LLC grew its position in CryoPort by 14.5% in the second quarter. Headlands Technologies LLC now owns 38,742 shares of the company’s stock worth $608,000 after acquiring an additional 4,906 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of CryoPort during the 2nd quarter valued at approximately $8,398,000. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.